BioMarin Pharmaceutical (BMRN) said Tuesday that it has completed its all-cash acquisition of Inozyme Pharma (INZY) for $270 million, or $4 per share.
The company said the move strengthens its enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy in development for ENPP1 Deficiency-a rare genetic disease that affects blood vessels, soft tissues, and bones.
The company said Inozyme shares have now been delisted from the Nasdaq Global Select Market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。